Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products
April 17 2018 - 7:04AM
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care, today announced it has
received four new regulatory approvals from the United Arab
Emirates Ministry of Health & Prevention. The family of
approved products include an acne treatment as well as anti-fungal
therapies, among others.
“These new MicroSafe products will further advance the common
methods for treating skin infections in a safer and more
efficacious manner,” said Safa Qadumi, managing director for the
MicroSafe Group, which is the exclusive distributor of Sonoma
Pharmaceutical products throughout the Middle East. “We anticipate
launching all four products immediately into pharmacies throughout
the United Arab Emirates.” The four approvals, all under the
provisions of the UAE’s General Sale List (GSL), encompass
hypochlorous acid-based products for treatment of acne as well as
anti-fungal indications.
“Sonoma remains very proud of its partnership with the MicroSafe
group and their expanding indications using Sonoma’s proprietary
Microcyn Technology. We are especially pleased with these UAE
approvals that should lead to adoption by other Middle Eastern
countries,” said Bruce Thornton, EVP of international operations
and sales for Sonoma Pharmaceuticals.
Contact MicroSafe Group at safa.microsafe@gmail.com for
distribution inquires relative to the Gulf and Middle Eastern
countries.
About MicroSafe GroupThe MicroSafe Group
distributes products manufactured by Sonoma Pharmaceuticals based
upon the Microcyn® Technology platform. The MicroSafe Group has
operations in several countries with its head office in Dubai,
United Arab Emirates. With several regional offices in the Middle
East as well as Australia, they provide innovative solutions to a
wide range of industries and healthcare providers. The MicroSafe
group promotes only those products it believes will truly
revolutionize healthcare – products that will enrich the lives of
patients and healthcare professionals all over the world.
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries. These forward-looking statements are
identified by the use of words such as “believe,” “achieve,” and
“strive,” among others. Forward-looking statements in this press
release are subject to certain risks and uncertainties inherent in
the company’s business that could cause actual results to vary,
including such risks that regulatory clinical and
guideline developments may change, scientific data may not be
sufficient to meet regulatory standards or receipt of required
regulatory clearances or approvals, clinical results may not
be replicated in actual patient settings, protection offered
by the company’s patents and patent applications may be
challenged, invalidated or circumvented by its
competitors, the available market
for the company’s products will not be as large as
expected, the company’s products will not be able to penetrate
one or more targeted markets, revenues will not be sufficient
to fund further development and clinical studies, as well as
uncertainties relative to varying product formulations and a
multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the company’s filings with the Securities and
Exchange Commission. The company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma® Pharmaceuticals is a registered trademark of Sonoma
Pharmaceuticals, Inc. All other trademarks and service marks are
the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFaddenVP of Public and Investor Relations(425)
753-2105dmcfadden@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Apr 2023 to Apr 2024